作者：
Framke, Elisabeth;Thygesen, Lau Caspar;Malmborg, Morten;Schou, Morten;Sellebjerg, Finn;...
通讯作者：
Framke, E
作者机构：
Copenhagen Univ Hosp, Dept Neurol, Danish Multiple Sclerosis Registry, Rigshosp, Valdemar Hansens Vej 2, DK-2600 Glostrup, Denmark.
Univ Southern Denmark, Natl Inst Publ Hlth, Copenhagen, Denmark.
Herlev & Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark.
Copenhagen Univ Hosp, Danish Multiple Sclerosis Ctr, Dept Neurol, Rigshosp, Glostrup, Denmark.
通讯机构：
Copenhagen Univ Hosp, Dept Neurol, Danish Multiple Sclerosis Registry, Rigshosp, Valdemar Hansens Vej 2, DK-2600 Glostrup, Denmark.
语种：
英文
关键词：
Fingolimod,multiple sclerosis,cardiovascular disease,CVD,safety,adverse events
期刊：
Multiple Sclerosis Journal
ISSN：
1352-4585
年：
2024
卷：
29
期：
SUPPL-3
页码：
368-368
会议名称：
9th Joint ECTRIMS-ACTRIMS meeting
会议时间：
OCT 11-13, 2023
会议地点：
Milan, ITALY
摘要：
Background: Fingolimod may be associated with risk of developing cardiovascular disease (CVD). Studies including reference groups and long follow-up are scarce. Objectives: We hypothesized that patients treated with fingolimod would be at higher risk of developing CVD compared to patients treated with natalizumab. Methods: A nationwide 12-year cohort study linking individual-level data from the Danish Multiple Sclerosis Registry with health registries on 2095 adult patients with multiple sclerosis (MS) without any health records of CVD at follow-up start. Exposure to fingolimod and natalizumab was defined by the first treatment of at least 3 months. Cohort entry was from ...
